I tend to agree , over a 21 year span and considering the...

First 33 Last

Share
Profile

Follow
prs

712 Posts.

61

05/10/17

13:39

Post #: 27683523
Share

Originally posted by Gipp ↑

I'm with you DavidW.......previous posts in this forum speculated a much higher Capex & even at $200 million still very bankable. The $60-$70 million Capex would have been a bonus but even the higher Capex number that has now come out should be amortised over a very long period given the 21 year plus mine life.

Other Lithium / Cobalt Companies are reporting Capex of $500 million plus so I don't see what the issue is.

They also seem to be concerned about the estimated Cobalt price at $72,000......again Cobalt has been as high as $61,500 in this current run - it could find itself at $72,000 by years end let alone during the mine's life.

Reading the comments regards the Cobalt Price by some seem to imply it needs to be $72,000 right now or by next week - this is a 21 year plus mine & a number provided by highly regarded professionals who do their research.....I actually think this number is conservative.

Someone mentioned they haven't heard from Solarbat??.....he stated last week he'll be away this week & out of internet & phone range so he is not ducking what's going on.....I'm sure we'll all hear from him next week.

Good luck everyone.

Expand

I tend to agree , over a 21 year span and considering the expected demand for cobalt over that term $72000 is very conservative.

There is still a LOT of money to be made if this gets funded and off the ground.

BAR Price at posting: 4.8¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 46 more messages in this thread...

First 33 Last

Add GSR (ASX) to my watchlist

I tend to agree , over a 21 year span and considering the...

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News